Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Feb 2;24(6):1187–1195. doi: 10.1016/j.bbmt.2018.01.039

Figure 4.

Figure 4.

Progression-free survival in patients with NHL (A) and MM (B) stratified by treatment group

A progression-free survival (PFS) event was defined as a report of disease progression, disease relapse, or death due to any cause. Assessment of PFS over 5 years showed no statistically significant difference in patients with non-Hodgkin’s lymphoma (A) (log-rank, P = .343; Wilcoxon, P = .396) or multiple myeloma (MM) (B) between the 2 treatment groups. In patients with MM, a non-significant (log-rank, P = .061; Wilcoxon, P = .138) trend toward shorter PFS in patients treated with plerixafor than in those receiving placebo.